Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Milrinone Lactate
Generic Name
Milrinone Lactate
Active Ingredient
MilrinoneCategory
Other
Salt Form
Lactate
Variants
22
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Milrinone Lactate, you must consult a qualified healthcare professional.
| 1 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 0143-9708 |
| 1 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 0409-0212 |
| 1 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 72485-501 |
| 1 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 0143-9374 |
| 1 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 65145-120 |
| 1 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 65145-122 |
| 1 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 70069-809 |
| 1 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 72485-502 |
| 1 mg/mL | INJECTION, SOLUTION | INTRAVENOUS | 42677-313 |
+ 10 more variants
Detailed information about Milrinone Lactate
Milrinone is a potent phosphodiesterase-3 (PDE3) inhibitor and inodilator used for the short-term management of acute decompensated heart failure to improve cardiac output and reduce vascular resistance.
Milrinone dosing must be highly individualized based on the patient's hemodynamic response (changes in blood pressure and heart function) and renal status. The standard protocol typically involves two phases:
Milrinone is not FDA-approved for use in pediatric patients; however, it is widely used off-label in pediatric intensive care units, particularly after congenital heart surgery. Dosing in children is highly specialized and often involves higher maintenance doses than adults (ranging from 0.25 to 0.75 mcg/kg/min) because children may clear the drug more rapidly. Pediatric use must be managed by a pediatric cardiologist or intensivist.
Because Milrinone is primarily excreted by the kidneys, patients with impaired renal function (kidney disease) require significant dose reductions to avoid toxicity. Healthcare providers use the Creatinine Clearance (CrCl) rate to adjust the infusion:
No specific dose adjustments are typically required for patients with liver disease, as hepatic metabolism plays a minor role in the clearance of Milrinone. However, clinical monitoring remains essential.
Older adults often have age-related declines in renal function. Therefore, healthcare providers often start at the lower end of the dosing spectrum and monitor kidney function (BUN and Creatinine) closely.
Milrinone is administered strictly via intravenous infusion. It is usually delivered through a central venous catheter (a large IV line) to ensure stable delivery and reduce the risk of vein irritation.
In a hospital setting, Milrinone is delivered by a programmed infusion pump. If the pump stops or the line becomes disconnected, it is considered a critical event. Healthcare providers must restart the infusion immediately, as the short half-life of the drug means its effects wear off quickly, which could lead to a rapid worsening of heart failure symptoms.
An overdose of Milrinone typically manifests as an exaggeration of its pharmacological effects. Signs include:
In the event of an overdose, the infusion must be stopped or slowed immediately. There is no specific antidote for Milrinone; treatment focuses on supportive care, such as intravenous fluids to support blood pressure and medications to manage heart rhythm issues.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to adjust infusion pump settings if you are a patient receiving home-based Milrinone therapy.
Milrinone is a potent medication, and side effects are relatively common due to its powerful impact on the cardiovascular system. The most frequently reported side effects include:
Milrinone is a high-alert medication that must only be administered under the supervision of medical professionals experienced in managing heart failure. The primary safety concerns revolve around its potential to induce dangerous heart rhythms and significantly lower blood pressure.
No FDA black box warnings for Milrinone. However, it is critical to note that the FDA explicitly warns against the long-term use of this medication in patients with chronic heart failure due to increased mortality risks.
There are no drugs that are strictly 'contraindicated' for use with Milrinone in the sense of a lethal chemical reaction; however, Furosemide (Lasix) and Bumetanide should never be mixed in the same intravenous line as Milrinone.
Milrinone must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a cardiologist include:
Milrinone is classified as FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, or there are no adequate and well-controlled studies in humans.
It is not known whether Milrinone is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Milrinone is administered to a nursing woman. Most clinicians recommend temporary cessation of breastfeeding while the mother is receiving an active infusion of Milrinone.
Milrinone is a selective inhibitor of the phosphodiesterase III (PDE3) isoenzyme. This enzyme is primarily found in cardiac muscle and vascular smooth muscle cells.
Common questions about Milrinone Lactate
Milrinone is primarily used for the short-term treatment of patients with acute decompensated heart failure (ADHF). It helps the heart pump more effectively by increasing the strength of the heart muscle contractions and relaxing the blood vessels to improve blood flow. Healthcare providers often use it in the hospital setting to stabilize patients who are experiencing severe shortness of breath or fluid buildup. It may also be used as a 'bridge' for patients awaiting a heart transplant or the surgical placement of a heart pump. Because of its potency, it is only administered intravenously under close medical supervision.
The most common side effects of Milrinone include headaches and various types of irregular heartbeats, known as arrhythmias. Specifically, ventricular arrhythmias occur in about 12% of patients, and ventricular tachycardia occurs in nearly 3%. Patients may also experience low blood pressure (hypotension), which can cause dizziness or lightheadedness. Because Milrinone makes the heart work harder, some patients may experience chest pain (angina). Doctors monitor patients continuously with an ECG to catch and treat these rhythm issues immediately.
Alcohol should be strictly avoided while being treated with Milrinone. Alcohol is a known myocardial depressant, meaning it can weaken the heart's ability to contract, which directly counteracts the purpose of Milrinone. Furthermore, alcohol can contribute to dehydration and electrolyte imbalances, increasing the risk of dangerous heart rhythms. Since Milrinone is used for severe heart failure, the heart is already in a fragile state, and alcohol consumption could lead to a rapid worsening of the condition. Always consult your cardiologist regarding lifestyle restrictions.
Milrinone is classified as FDA Pregnancy Category C, meaning there is limited data on its safety in humans. Animal studies have suggested potential risks, but well-controlled studies in pregnant women are lacking. It is generally only used during pregnancy if the mother's life is at risk and no safer alternatives are available. If you are pregnant or planning to become pregnant, it is vital to discuss the risks and benefits with your healthcare team. The drug's effect on a developing fetus is not fully understood, and it should be used with extreme caution.
Milrinone works very quickly when administered intravenously. If a loading dose is given, improvements in heart function and blood pressure can often be measured within 5 to 15 minutes. For most patients, the full therapeutic effect is reached within 30 to 60 minutes of starting the continuous infusion. Patients often notice an improvement in their breathing and a reduction in fatigue as the heart begins to pump blood more efficiently. However, because it works so fast, it also clears the body quickly, meaning the infusion must not be interrupted.
No, Milrinone should not be stopped suddenly without medical supervision. Because the drug has a short half-life, its effects on the heart and blood vessels wear off within a few hours. If the infusion is stopped abruptly, a patient may experience 'rebound' heart failure, where symptoms like shortness of breath and fluid retention return rapidly and severely. Doctors typically 'wean' patients off the drug by slowly lowering the dose over several hours or days while monitoring the patient's stability. If you are on home Milrinone therapy, never turn off the pump unless instructed by a doctor.
In a hospital setting, Milrinone is delivered via a continuous pump, so a 'missed dose' usually means the pump has stopped or the IV line has come out. This is a medical emergency for a heart failure patient. You must alert your nurse or doctor immediately if the pump alarms or if you notice the medicine is not flowing. If you are receiving Milrinone at home and the infusion is interrupted, call your home health agency or emergency services immediately. Rapidly declining levels of the drug in your blood can cause your heart failure to worsen quickly.
Milrinone itself does not cause weight gain; in fact, it often leads to weight loss in heart failure patients. This is because the drug helps the heart pump better, which allows the kidneys to work more efficiently and remove excess fluid from the body. Patients with heart failure often carry 'water weight,' and as Milrinone improves circulation, this fluid is excreted as urine. If you notice rapid weight gain while on Milrinone, it usually means the heart failure is worsening, and you should contact your healthcare provider immediately. Monitoring daily weights is a standard part of therapy.
Milrinone can interact with several other medications, particularly those that also affect blood pressure or heart rhythm. It is often used alongside diuretics (water pills) and other heart medications, but this requires very careful monitoring of potassium levels and blood pressure. It should not be mixed in the same IV line with Furosemide (Lasix), as they will form a solid precipitate. Always provide your doctor with a full list of your medications, including over-the-counter supplements, to prevent dangerous interactions. Your medical team will adjust your other doses as needed while you are on Milrinone.
Yes, Milrinone lactate is available as a generic medication and is widely used in hospitals in this form. The brand name version, Primacor, is also available, but the generic version is chemically identical and equally effective. Because it is an intravenous medication used in acute care, the cost is typically covered as part of the hospital stay or through specialized home infusion insurance coverage. The availability of the generic has made this life-saving treatment more accessible for intensive care units and heart failure clinics worldwide.
Other drugs with the same active ingredient (Milrinone)
> Warning: Stop taking Milrinone and call your doctor immediately if you experience any of these symptoms while receiving home therapy or alert your nurse immediately if in the hospital.
Milrinone is strictly intended for short-term use. Clinical data from the PROMISE Trial (1991) showed that long-term use of oral PDE3 inhibitors in patients with Class III or IV heart failure was associated with an increased risk of sudden death, likely due to lethal arrhythmias. In the modern era, some patients receive 'chronic' home-based IV Milrinone as palliative care. Long-term effects in these patients include:
No FDA black box warnings currently exist for Milrinone. However, the FDA-approved labeling contains a 'Precautions' section that is essentially treated with the same clinical gravity: Milrinone should not be used for long-term treatment of heart failure patients because it has been shown to increase the risk of hospitalization and death without providing a long-term benefit to survival.
Report any unusual symptoms to your healthcare provider immediately. Monitoring of electrolytes and platelet counts is standard clinical practice during Milrinone therapy.
Patients receiving Milrinone require intensive monitoring, including:
Milrinone is administered to patients who are typically too ill to drive or operate machinery. Furthermore, side effects like dizziness from low blood pressure or headaches would make these activities unsafe.
There are no direct chemical interactions between Milrinone and alcohol; however, alcohol is a myocardial depressant (it weakens the heart muscle) and can worsen heart failure. Patients requiring Milrinone should strictly avoid alcohol.
Milrinone does not typically require a 'taper' in the traditional sense, but the infusion is usually reduced gradually (e.g., from 0.5 to 0.375 to 0.25 mcg/kg/min) while observing the patient for 'rebound' heart failure symptoms. If the patient's blood pressure or breathing worsens during the step-down, the higher dose may be resumed.
> Important: Discuss all your medical conditions, especially kidney disease or recent heart attacks, with your healthcare provider before starting Milrinone.
Since Milrinone is administered intravenously, food does not affect its absorption. However, patients on Milrinone are typically on a strict low-sodium (salt) diet and may have fluid restrictions (e.g., 1.5 to 2 liters per day) to manage their heart failure.
Milrinone does not significantly interfere with most standard laboratory tests. However, it can occasionally cause a false elevation in the readings of certain types of cardiac monitors if they are not calibrated for patients on inotropic support. It may also lead to changes in serum potassium and platelet counts, which will be reflected in lab results.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those for blood pressure or rhythm control.
There is no documented cross-sensitivity between Milrinone and other classes of heart medications like ACE inhibitors or Beta-blockers. However, patients who have had a reaction to Inamrinone (an older PDE3 inhibitor) should be monitored closely, although the chemical structures are distinct enough that an allergy to one does not guarantee an allergy to the other.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of heart valve problems or kidney disease, before prescribing Milrinone.
Safety and effectiveness in pediatric patients have not been established by the FDA. Despite this, Milrinone is a 'standard of care' in pediatric cardiac ICUs.
Clinical studies of Milrinone did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, the primary concern in the elderly is renal clearance.
Renal impairment significantly prolongs the half-life of Milrinone.
While no specific dose adjustment is required for liver disease, patients with 'cardiac cirrhosis' (liver damage caused by chronic heart failure) may have complex fluid and electrolyte issues that require careful management during Milrinone therapy.
> Important: Special populations require individualized medical assessment and often require care in a specialized cardiac intensive care unit.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (Intravenous) |
| Protein Binding | 70% |
| Half-life | 2.3 hours (Normal Renal) |
| Tmax | Immediate (IV) |
| Metabolism | 12% Hepatic (O-glucuronide) |
| Excretion | Renal 83% (Unchanged) |
Milrinone is a Phosphodiesterase-3 Inhibitor and an Inodilator. It is functionally similar to Inamrinone (which is no longer widely used) and Cilostazol (though Cilostazol is used for peripheral vascular disease rather than acute heart failure).